Recently, ERbeta was demonstrated to inhibit androgen receptor signaling in the prostate and thus is likely to play a pivotal role in the regulation of prostate growth and differentiation. The objective of this proposal is to elucidate the role of ERbeta in androgen-responsive prostate cell models. To do this, ERbeta-interacting proteins will be identified using a T7 phage display system. Following the validation of these protein-protein interactions, we propose to determine the role of these proteins in modulating the physiological and pharmacological actions of ERbeta in androgen-mediated prostate growth mechanisms. To accomplish this, we propose the following specific aims:
Aim 1. Identification of factors that interact with ERbeta-ligand complexes in androgen-responsive prostate model cell lines.
Aim 2. Validation and characterization of ERbeta-interacting proteins in mammalian cells.
Aim 3. Evaluation of the biological consequences of differential ERbeta-cofactor recruitment in androgen-responsive prostate cell lines.
| Wardell, Suzanne E; Ilkayeva, Olga R; Wieman, Heather L et al. (2009) Glucose metabolism as a target of histone deacetylase inhibitors. Mol Endocrinol 23:388-401 |
| Frigo, Daniel E; Sherk, Andrea B; Wittmann, Bryan M et al. (2009) Induction of Kruppel-like factor 5 expression by androgens results in increased CXCR4-dependent migration of prostate cancer cells in vitro. Mol Endocrinol 23:1385-96 |
| Sherk, Andrea B; Frigo, Daniel E; Schnackenberg, Christine G et al. (2008) Development of a small-molecule serum- and glucocorticoid-regulated kinase-1 antagonist and its evaluation as a prostate cancer therapeutic. Cancer Res 68:7475-83 |
| Frigo, Daniel E; McDonnell, Donald P (2008) Differential effects of prostate cancer therapeutics on neuroendocrine transdifferentiation. Mol Cancer Ther 7:659-69 |
